tiprankstipranks
Advertisement
Advertisement

APGE Stock Latest News

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Market NewsM&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
1d ago
ABBV
APGE
Apogee Therapeutics Shareholders Back Board, Auditors, Compensation
PremiumCompany Announcements
Apogee Therapeutics Shareholders Back Board, Auditors, Compensation
8d ago
8K
APGE
Salveen Richter Reiterates Hold on Apogee; Maintains $89 Price Target Amid Long-Term Promise and Pipeline Uncertainty
PremiumRatings
Salveen Richter Reiterates Hold on Apogee; Maintains $89 Price Target Amid Long-Term Promise and Pipeline Uncertainty
9d ago
APGE
Apogee Therapeutics price target raised to $97 from $82 at RBC Capital
PremiumThe Fly
Apogee Therapeutics price target raised to $97 from $82 at RBC Capital
12d ago
APGE
Apogee Therapeutics moved to Neutral at Goldman Sachs
PremiumThe Fly
Apogee Therapeutics moved to Neutral at Goldman Sachs
23d ago
APGE
Analyst Reaffirms Buy on Apogee as Zumilokibart Data Strengthens Case; $137 Price Target Maintained
PremiumRatingsAnalyst Reaffirms Buy on Apogee as Zumilokibart Data Strengthens Case; $137 Price Target Maintained
24d ago
APGE
Apogee Therapeutics price target lowered to $81 from $83 at Truist
Premium
The Fly
Apogee Therapeutics price target lowered to $81 from $83 at Truist
24d ago
APGE
Apogee Therapeutics price target raised to $135 from $120 at Wedbush
Premium
The Fly
Apogee Therapeutics price target raised to $135 from $120 at Wedbush
24d ago
APGE
Apogee Advances Zumilokibart After Positive Phase 2 Results
PremiumCompany Announcements
Apogee Advances Zumilokibart After Positive Phase 2 Results
24d ago
8K
APGE
Apogee Therapeutics Secures Major Non-Dilutive Blackstone Financing
PremiumCompany Announcements
Apogee Therapeutics Secures Major Non-Dilutive Blackstone Financing
24d ago
8K
APGE
Apogee Therapeutics announces $1.3B financing pact with Blackstone Life Sciences
PremiumThe Fly
Apogee Therapeutics announces $1.3B financing pact with Blackstone Life Sciences
24d ago
APGE
Apogee Therapeutics reports ‘positive’ results from Part B of Phase 2 APEX trial
PremiumThe Fly
Apogee Therapeutics reports ‘positive’ results from Part B of Phase 2 APEX trial
24d ago
APGE
Michael Yee Reaffirms Buy on Apogee, Citing Differentiated Zumilokibart Profile, Upcoming Data Catalysts, and Maintained $100 Price Target
PremiumRatingsMichael Yee Reaffirms Buy on Apogee, Citing Differentiated Zumilokibart Profile, Upcoming Data Catalysts, and Maintained $100 Price Target
1M ago
APGE
Analyst Reiterates Buy on Apogee, Maintains $137 Price Target on Strong Zumilokibart Profile and Pipeline Upside
Premium
Ratings
Analyst Reiterates Buy on Apogee, Maintains $137 Price Target on Strong Zumilokibart Profile and Pipeline Upside
1M ago
APGE
Apogee Therapeutics initiated with a Buy at Rothschild & Co Redburn
Premium
The Fly
Apogee Therapeutics initiated with a Buy at Rothschild & Co Redburn
2M ago
APGE
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift
PremiumCompany Announcements
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift
2M ago
8K
APGE
APGE: Best-in-Class Potential for Zumilokibart in Atopic Dermatitis Supports Undervalued Buy Rating
PremiumRatings
APGE: Best-in-Class Potential for Zumilokibart in Atopic Dermatitis Supports Undervalued Buy Rating
3M ago
APGE
Apogee Therapeutics price target raised to $110 from $105 at Mizuho
PremiumThe Fly
Apogee Therapeutics price target raised to $110 from $105 at Mizuho
3M ago
APGE
Apogee Therapeutics Prices Upsized Public Equity Offering
PremiumCompany Announcements
Apogee Therapeutics Prices Upsized Public Equity Offering
3M ago
8K
APGE
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
PremiumThe FlyMidday Fly By: Merck to acquire Terns, Arm CPU launch applauded
3M ago
GM
AMD
Apogee Therapeutics 5M share Secondary priced at $70.00
Premium
The Fly
Apogee Therapeutics 5M share Secondary priced at $70.00
3M ago
APGE
Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
Premium
The Fly
Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
3M ago
APGE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >